Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 25, 2018

Primary Completion Date

December 31, 2023

Study Completion Date

May 31, 2024

Conditions
Ovarian Cancer
Interventions
DRUG

Enoxaparin

Enoxaparin is used for prevention of blood clots following abdominal or orthopedic surgery and in medical patients with restricted mobility during acute illness

DRUG

Enoxaparin + Rosuvastatin

"Rosuvastatin is an anti-cholesterol medication that is FDA (the U.S. Food and Drug Administration) approved to lower cholesterol and reduce the risk of arterial blood clots. There is evidence that rosuvastatin can lower the risk of venous blood clots in healthy individuals~Enoxaparin is used for prevention of blood clots following abdominal or orthopedic surgery and in medical patients with restricted mobility during acute illness"

OTHER

Thromboprophylaxis

standard of care therapy

Trial Locations (2)

02214

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Beth Israel Deaconess Medical Center

OTHER

NCT03532139 - Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study) | Biotech Hunter | Biotech Hunter